New infusion aims to train immune system to handle gluten

NCT ID NCT05660109

First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 17 times

Summary

This study tested a new medicine called TPM502 in 28 adults with celiac disease. Participants received two infusions of TPM502 or a placebo, two weeks apart. The goal was to see if the treatment is safe and if it can help the body become more tolerant to gluten, potentially reducing reactions to accidental exposure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CRST Oy

    Turku, FI-20520, Finland

  • Centre for Human Drug Research

    Leiden, 2333 ZA, Netherlands

  • Charite' Hospital

    Berlin, 12200, Germany

  • Clinical Trial Consultants, Uppsala University

    Uppsala, 752 37, Sweden

  • Oslo University Hospital HF - Rikshospitalet

    Oslo, 0372, Norway

  • Royal Adelaide Hospital

    Adelaide, 5000, Australia

  • University Hospital of North-Norway

    Tromsø, 9038, Norway

  • Wesley Research Institute

    Brisbane, 4066, Australia

Conditions

Explore the condition pages connected to this study.